

## Conference Program

### Monday, February 6

**6:30 p.m.-8:00 p.m. Opening Keynote Presentations**

Grand Cypress DEF

*Co-Chairpersons: Charles L. Sawyers, Memorial Sloan-Kettering Cancer Center, New York, NY; and Arul M. Chinnaiyan, University of Michigan, Ann Arbor, MI*

**COP1: Tumor suppressor role revealed**

Vishva M. Dixit, Genentech, Inc., South San Francisco, CA

**Polycomb-dependent and -independent functions of EZH2 in prostate cancer**

Myles Brown, Dana-Farber Cancer Institute, Boston, MA

**8:00 p.m.-9:30 p.m. Networking Reception**

Upper Pool Deck 1&2

### Tuesday, February 7

**7:30 a.m.-8:30 a.m. Continental Breakfast**

Portico West

**8:30 a.m.-10:00 a.m. Session 1: Genomics/Molecular Profiling**

Grand Cypress DEF

*Chairperson: Elaine Mardis, Washington University School of Medicine, St. Louis, MO*

**Genomic comparisons of coincident prostate cancer foci**

Elaine Mardis

**Functional implications of relocation of regulated transcription units in prostate cancer**

Michael (Geoff) Rosenfeld, University of California San Diego, La Jolla, CA

**Outcome prediction from the pattern of aberrations in prostate cancer genomes**

Barry S. Taylor, Memorial Sloan-Kettering Cancer Center, New York, NY

**10:00 a.m.-10:20 a.m. Break**

Portico West

**10:20 a.m.-11:20 a.m. Session 2: Genomics/Molecular Profiling – Prognostic Signatures**

Grand Cypress DEF

*Chairperson: Elaine Mardis, Washington University School of Medicine, St. Louis, MO*

[PLEASE NOTE: This session is not accredited for CME credit.]

**Biological pathways predictive of clinically significant prostate cancer in the context of tumor heterogeneity**

Steven Shak, Genomic Health, Redwood City, CA

**Cell cycle progression genes differentiate indolent from aggressive prostate cancer**

Steve Stone, Myriad Genetics, Salt Lake City, UT

**Development of integrated diagnostic methods for tissue testing**

Gary Pestano, Ventana, a member of the Roche Group, Oro Valley, AZ

**11:20 a.m.-12:50 p.m. Session 3: Androgen Receptor Signaling**

Grand Cypress DEF

*Chairperson: Karen Knudsen, Jefferson University Hospital, Philadelphia, PA*

**Mechanisms regulating distinct AR transcriptional programs in PCa**

Steven Balk, Beth Israel Deaconess Medical Center, Boston, MA

**Cross talk of the androgen receptor and DNA damage pathways: Molecular and translational prostate cancer relevance**

Karen Knudsen

**Overcoming castration-resistant prostate cancer**

Charles L. Sawyers, Memorial Sloan-Kettering Cancer Center, New York, NY

**12:50 p.m.-3:20 p.m. Poster Session A/Lunch**

Regency Hall 1-4

**3:20 p.m.-4:50 p.m. Session 4: Drug Development**

Grand Cypress DEF

*Chairperson: Johann S. deBono, Institute of Cancer Research, Sutton, United Kingdom*

**Immune checkpoint blockade in prostate cancer: New insights and opportunities**

James Allison, Memorial Sloan-Kettering Cancer Center, New York, NY

**Cabozantinib (XL-184) and prostate cancer: Preclinical and clinical profile of a novel agent**

Maha Hussain, University of Michigan Medical School, Ann Arbor, MI

**Conducting hypothesis testing trials for the treatment of advanced prostate cancer**

Johann S. deBono

**5:00 p.m.-7:30 p.m. Poster Session B/Reception**  
Regency Hall 1-4

**7:30 p.m. Evening off/Dinner on own**

## **Wednesday, February 8**

**7:30 a.m.-8:30 a.m. Continental Breakfast**  
Portico West

**8:30 a.m.-10:00 a.m. Session 5: ETS Gene Fusions**  
Grand Cypress DEF  
*Chairperson: Mark A. Rubin, Cornell University Weill Medical College, New York, NY*

**Recurrent *SPOP* mutations define a distinct molecular subclass of prostate cancer**  
Mark A. Rubin

**Novel therapeutic targets in prostate cancer**  
Arul M. Chinnaiyan, University of Michigan, Ann Arbor, MI

**Context-specific oncogenesis by ETS family transcription factors**  
Yu Chen, Memorial Sloan-Kettering Cancer Center, New York, NY

Title to be announced  
Felix Feng, University of Michigan, Ann Arbor, MI

**10:00 a.m.-10:20 a.m. Break**

**10:20 a.m.-11:50 a.m. Session 6: Prostate Cancer Initiation and Progression**  
Grand Cypress DEF  
*Chairperson: Michael Shen, Columbia University, New York, NY*

**Stem cells and the origin of prostate cancer**  
Michael Shen

**Mechanisms and therapeutic targets in metastatic prostate cancer**  
Karen Cichowski, Harvard University, Cambridge, MA

**Stem cells and prostate cancer**  
Owen N. Witte, University of California, Los Angeles, CA

**12:00 p.m.-2:30 p.m. Poster Session C/Lunch**

Regency Hall 1-4

**2:30 p.m.-5:00 p.m. Session 7: Late-Breaking Research Session**

Grand Cypress DEF

*Co-Chairpersons: Charles L. Sawyers, Memorial Sloan-Kettering Cancer Center, New York, NY; and Arul M. Chinnaiyan, University of Michigan, Ann Arbor, MI*

**Altered AR gene architecture and splicing in castration-resistant prostate cancer**

Scott M. Dehm, University of Minnesota Masonic Cancer Center, Minneapolis, MN

**Cooperation between androgen receptor and Polycomb in prostate cancer**

Jindan Yu, Northwestern University, Chicago, IL

**A bad influence: ERG, AR, and prostate cell differentiation**

Ray Pagliarini, Novartis, East Hanover, NJ

**Transcriptional programs directed by the androgen receptor splicing variants**

Jun Luo, Johns Hopkins Medical Institutions, Baltimore, MD

**Oncogenic ETS overexpression mimics RAS/MAPK signaling in prostate cells\***

Peter C. Hollenhorst, Indiana University, Bloomington, IN

**Optimization and applications of a tissue slice culture model of the normal and malignant human prostate\***

Sophia L. Maund, Stanford University, Stanford, CA

**The snoRNP assembly factor SHQ1 is a novel prostate cancer tumor suppressor gene\***

Phillip J. Iaquinta, Memorial Sloan-Kettering Cancer Center, New York, NY

**Biochemical recurrence is not a definitive surrogate endpoint for development of clinically useful predictive models for post-prostatectomy patients\***

Anamaria Crisan, GenomeDx, Vancouver, BC, Canada

**Therapeutic targeting of oncogene-specific tyrosine kinase networks during prostate cancer progression\***

Justin M. Drake, University of California, Los Angeles, CA

**Cabozantinib (XL184) inhibits androgen-sensitive and castration-resistant prostate cancer in the bone and increases bone formation in nontumored bones\***

Eva Corey, University of Washington, Seattle, WA

**5:00 p.m.**

**Evening off/Dinner on own**

\*Short talks from proffered papers

## Thursday, February 9

**7:30 a.m.-8:30 a.m. Continental Breakfast**  
Portico West

**8:30 a.m.-10:00 a.m. Session 8: Imaging**  
Grand Cypress DEF  
*Chairperson: Martin G. Pomper, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD*

**Molecular imaging of androgen receptor signaling in CRPC**  
Steven M. Larson, Memorial Sloan-Kettering Cancer Center, New York, NY

**Diagnosing prostate cancer with image fusion (MRI, PET, CT, US)**  
Peter Choyke, National Cancer Institute, Bethesda, MD

**Molecular imaging agents for prostate cancer: Focus on PSMA**  
Martin G. Pomper

**10:00 a.m.-10:30 a.m. Break**  
Portico West

**10:30 a.m.-12:30 p.m. Session 9: Closing Keynotes and Panel Discussion**  
Grand Cypress DEF  
*Co-Chairpersons: Arul M. Chinnaiyan, University of Michigan, Ann Arbor, MI; and Charles L. Sawyers, Memorial Sloan-Kettering Cancer Center, New York, NY*

**Inflammation as the trigger of somatic epigenome defects in prostate cancer**  
William G. Nelson, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD

**Role of the microenvironment in prostate cancer progression and resistance**  
Christopher J. Logothetis, The University of Texas MD Anderson Cancer Center, Houston, TX

**Panelists:**

- Arul M. Chinnaiyan, University of Michigan, Ann Arbor, MI
- Christopher J. Logothetis, The University of Texas MD Anderson Cancer Center, Houston, TX
- William G. Nelson, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD
- Charles L. Sawyers, Memorial Sloan-Kettering Cancer Center, New York, NY

**12:30 p.m. Departure**